blood product News
-
On the road with ZipThaw
We’ve been on the road introducing ZipThaw, the revolutionary blood product thawing device, to military and civilian clinicians. This week we’re in Washington DC with Mark Rosenfeld of Genesis BPS. Here are some outtakes from the various shows and exhibitions. We’re grateful for the interest and flurry of new orders. ZipThaw is currently in use across the world! ...
-
Improve Staff Productivity
ZipThaw is a blood product thawer that uses revolutionary dry technology to quickly thaw blood products for patients in need. ZipThaw is dry, so there’s no messes like with water baths, and fast, so you can increase your thawed plasma throughput — it’s also easy for staffers to use. With simple thawing, staffers can spend their time elsewhere on other critical tasks. Last ...
-
Time for a better way to thaw
For decades, medical professionals have used slow, cumbersome, imprecise water baths to thaw plasma. It’s time for a better way! Introducing ZipThaw: a dry, portable, rapid thawing device combined with our disposable ZipSleeve® anti-contamination barrier with heat sensors. As an alternative to water baths, dry plasma thawing is a groundbreaking innovation that unlocks numerous ...
-
Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures
Kurin. Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO. The agreement is sole source and is for three years. “AllSpire Health GPO and Kurin are committed to patient safety by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing ...
By Kurin, Inc.
-
HumanPeople Incorporate TAP II for Home Collection of Blood Samples
Our customer HumanPeople, a UK based personalized health company, announced plans to enhance their service by integrating TAP II, following our recent CE Mark. We are thrilled to see TAP II, the blood collection product we designed, solving problems for them. Below are a few lines from their post highlighting how TAP II helped HumanPeople improve their customer experience and efficiencies. ...
-
S.F.-based startup raises $25M to expand blood collection technologies
San Francisco medical device company Velano Vascular closed a $25 million second round of financing, bringing its total overall to $50 million. The new capital will go toward expanding its needle-less blood draw device and to developing new technologies. CEO Eric Stone would not reveal what these new technologies will entail but said they will fall within the company’s mission ...
-
Atelerix presents promising data for the application of its technology LeukoStor™ to Monocyte Preservation
Peripheral blood mononuclear cells (PBMCs), derived from whole blood or leukapheresis, encompass several major immune cell populations including lymphocytes, monocytes, NK cells and dendritic cells. Apheresis material is a PBMC-enriched blood product widely used in cell therapy, the maximum shelf life of which is 48h when supplied fresh. The collection, processing, and shipment of fresh apheresis ...
By Atelerix Ltd
-
Gauss Surgical to Present Triton at UHC Annual Conference
Gauss Surgical, Inc. announced today that the company will compete in the annual “UHC Startup Challenge”, which will take place on Friday, October 2 in Orlando as part of the “Advance: UHC Annual Conference 2015”. The company will have the opportunity to present Triton, the world’s first and only mobile platform for real-time monitoring of surgical blood loss, to the ...
-
Gauss Surgical Announces FDA 510(k) Clearance of Triton Canister App for Accurate Surgical Blood Loss Monitoring
Gauss Surgical today announced that the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Triton Canister App, the second core product in its Triton System™ portfolio, the world’s first and only mobile platform for real-time monitoring of surgical blood loss. Now, in addition to estimating blood loss on surgical sponges, the system can accurately ...
-
Kurin, Inc. announces UK clinical study results showing significant decrease in blood culture contaminations with the Kurin Lock™
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today a new clinical study supporting the efficacy of their blood culture collection product. Authors from Guy’s and St. Thomas’ NHS Foundation Trust, a prestigious London-based hospital, presented their data at the recent Infection Prevention Society conference in ...
By Kurin, Inc.
-
Grifols and Shanghai RAAS close their strategic alliance in China
Grifols controls a 26.20% stake in Shanghai RAAS (economic and voting rights) in exchange for a non-majority share on behalf of Shanghai RAAS (45% economic rights and 40% voting rights) in Grifols’ subsidiary, Grifols Diagnostic Solutions (GDS) Over the past 35 years, Grifols has increasingly expanded its presence in China, which is currently the company’s third-largest sales ...
-
Hemostemix Announces Rick Groome as Special Advisor to the CEO
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce Mr. Richard (“Rick”) Groome has joined Hemostemix as a special advisor to the CEO, focused on completing a series of financing transactions. Over the last three decades Mr. Groome was instrumental in creating and building two securities firms, Marleau ...
-
Hemostemix Announces Soft Lock of Database as Source Document Verification Completed
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal ...
-
Pronalyse Supports Drug Discovery with the Launch of Biosimilar Analysis Solutions
Pronalyse is a protein characterization division of Creative Proteomics, an integrated CRO with rich experience in providing drug development services. Based on years of experience supporting the development of biosimilars, Creative Proteomics can provide comprehensive Biosimilar Analysis Solutions. A biosimilar is a biological product that is similar to an approved biological originator, ...
-
BloodCenter of Wisconsin and Eastman Chemical Company announce new blood bag clinical trial results
BloodCenter of Wisconsin (BCW, part of Versiti) and Eastman Chemical Company (NYSE:EMN) have announced the results of a recent clinical trial evaluating a new plasticizer for blood bags. While di-2-ethylhexyl phthalate (DEHP) has provided the medical industry with a stable ortho-phthalate plasticizer for many years, regulatory trends and consumer demands will inevitably drive the industry to ...
-
Hemostemix Announces Settlement Agreement
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce that it has entered into a settlement agreement (the “Settlement Agreement”) with Aspire Health Science, LLC ...
-
Gauss Raises $20 Million in Series C From Northwell Health Softbank Ventures Korea for AI-Enabled Platform for the Operating Room
Gauss Surgical, an AI-driven healthcare technology company, raised $20 million in Series C funding from Northwell Health and SoftBank Ventures Korea, the global early-stage venture capital arm of SoftBank Group, as well as from the LS Polaris Innovation Fund and seven other leading US health systems. The proceeds of the round will be used to accelerate the adoption of its Triton platform in ...
-
Hemostemix Announces Closing of UNIT Private Placement
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) announces that it has closed its previously announced non-brokered private placement of units (“Units”) announced on February 2, 2022, for gross proceeds of $1,204,849.92 (the “Offering”). The Offering consisted of the issuance of an aggregate of 8,606,071 Units at a price of ...
-
Abbott receives FDA approval for first fully automated blood test for `kissing bug` disease
Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug." ...
-
dBMEDx Offers Big Results with Small Equipment
The tricorder was a multifunctional device used for sensor scanning, recording and analyzing data to help diagnose disease and collect bodily information about a patient. That fictional object of the future is — in current day — becoming a reality, thanks to dBMEDx, a company offering a hand-held ultrasound scanner called the BBS Revolution that can be used for medical assessments. ...
By dBMEDx
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you